View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 19, 2022

Eisai enrols first patient in Phase II/III Alzheimer’s disease antibody trial

DIAN-TU selected E2814 as the first investigational therapy for the trial analysing anti-tau drugs in March last year.

Eisai has enrolled the first subject in the Phase II/III Tau NexGen clinical trial of its investigational anti-microtubule binding region (MTBR) tau antibody, E2814, for dominantly inherited Alzheimer’s disease (DIAD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The patient was enrolled at Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) led by Washington University School of Medicine in St Louis.

Eisai created E2814 through a research partnership with University College London. 

Currently being developed as a disease altering agent for tauopathies such as sporadic AD, the MTBR tau antibody can potentially avert the tau seed spread within the brains of affected individuals.

The Tau NexGen trial will analyse the tolerability, safety, biomarker, and cognitive efficacy of investigational treatments in pre-symptomatic or symptomatic subjects with an AD-causing gene mutation. 

DIAN-TU chose E2814 as the first investigational therapy among anti-tau drugs for the trial in March last year.

Symptomatic subjects will be given anti-amyloid β (Aβ) protofibril antibody lecanemab for a duration of six months and randomised to receive the anti-tau drug or a placebo. 

As amyloid plaques deposit before tau tangles in AD, the trial design permits the researchers to determine whether removal of amyloid clears the way for the efficient functioning of the anti-tau drug.

On obtaining positive data in the primary and secondary endpoints in the assessment two years following trial commencement, the study will be expanded for additional two years to evaluate if the drug can decelerate cognitive decline and has an added impact on tau pathology.

Individuals with DIAD genetic mutations could develop AD and also have chances of developing symptoms at nearly the same age as their affected parents did. 

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena